Analysts expect Immunovant, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.28 M | 6.61 M | 7.44 M | 95.02 M | |||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.86 M | 5.50 M | 6.33 M | 79.20 M | |||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.07 M | 6.06 M | 6.89 M | 87.11 M |
Analysts expect Immunovant, Inc. to report earnings per share of -0.79 for Q2 26, against a range of -0.84 to -0.74. The most recent reported quarter, Q1 26, came in at -0.75, a 25.0% miss against the -0.60 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.74 | -0.76 | -0.64 | -0.71 | -0.73 | -0.61 | -0.73 | -0.75 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -0.57 | -0.75 | -0.63 | -0.61 | -0.63 | -0.69 | -0.61 | -0.58 | -0.74 | -0.71 | -0.71 | -0.66 | -0.64 | -0.65 | -0.75 | -0.51 | |||||||||||
| Low Estimate | -0.67 | -0.81 | -0.71 | -0.71 | -0.75 | -0.83 | -0.65 | -0.62 | -0.84 | -0.79 | -0.81 | -0.74 | -0.78 | -0.69 | -0.81 | -0.59 | |||||||||||
| Consensus Estimate | -0.62 | -0.78 | -0.67 | -0.66 | -0.69 | -0.76 | -0.63 | -0.60 | -0.79 | -0.75 | -0.76 | -0.70 | -0.71 | -0.67 | -0.78 | -0.55 |
Pull Wall Street consensus for Immunovant, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=IMVT&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "IMVT", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=IMVT&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();